OncoVista Innovative Therapies, Inc. (OVIT.OB) Subsidiary Inks Deal for Research Project for Innovative Breast Cancer Testing

QualityStocks would like to highlight OncoVista Innovative Therapies, Inc. (OTCBB: OVIT). OncoVista Innovative Therapies is a biopharmaceutical company involved in the development of targeted anticancer therapies by using tumor-associated biomarkers. In conjunction with its subsidiary, AdnaGen AG which is based in Langenhagen, Germany, the Company has developed and currently markets patented diagnostic kits in Europe for the detection of circulating tumor cells in patients with breast, colon, ovarian and prostate cancers under the brand name AdnaGen™.

In the company’s news yesterday,

OncoVista Innovative Therapies Inc. announced that its wholly owned subsidiary AdnaGen AG, a manufacturer of CE-certified circulating tumor cell (CTC) diagnostic assays, has secured an agreement with TATAA Molecular Diagnostics for exclusive use of its Adnatest™ BreastCancer assays.

The agreement results in a three-year international breast cancer research project, COHERTA. According to AdnaGen AG, the Adnatest™ BreastCancer diagnostic blood test can lead to more effective evaluation and cost effective treatments without toxic side-effects.

The purpose of the COHERTA project is to identify more applications for CTC testing. TATAA Molecular Diagnostics and Czech Academy of Science have conducted collaborative research since 2008, and have played an integral role in demining the effectiveness of AdnaGen AG’s new prognostic and predictive biomarkers.

The international COHERTA study will take place in the Czech Republic and Slovakia, and will focus on finding the relationship between metastasic tumors and HER2, the most aggressive type of breast cancer, which is diagnosed in one out of three breast cancers.

Researchers will conduct the tests using the Adnatest™ BreastCancer assay, and believe that through monitoring and research, a new application of the test could be used for patients with breast cancer relapse. Currently, the only way to evaluate the HER2-status of a tumor is through a biopsy of the tumor tissue.

“OncoVista Innovative Therapies Inc. is very pleased that AdnaGen’s Adnatest™ BreastCancer assays are being used exclusively in the COHERTA study. This next phase is another important step in identifying blood-based diagnostic and monitoring assays that work to the patient’s benefit,” Dr. Alexander L. Weis, president and CEO of OncoVista stated in the press release. “The Adnatest™ BreastCancer is just one of several on which OncoVista has been working on. It’s subsidiary, AdnaGen AG, has also been developing and testing other CE-certified circulating tumor cell (CTC) diagnostic assays for prostate and colon cancers. Together with breast cancers, prostate and colon cancers are the three most frequent types of cancer diagnosed today.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.